APO RESEARCH · REPORT
Drugs for Malaria
Drugs for malaria or antimalarial medications are also known as anti-malarial drugs. Anti-malarial drugs treat or Prevention malaria, a disease that occurs in tropical, subtropical, and some temperate regions of the world. The disease is caused by a parasite, Plasmodium, which belongs to a group of one-celled organisms known as protozoa. The only way to get malaria is to be bitten by a certain type of mosquito that has bitten someone who has the disease.
Product & engineering
Understand the product.
Drugs for malaria or antimalarial medications are also known as anti-malarial drugs. Anti-malarial drugs treat or Prevention malaria, a disease that occurs in tropical, subtropical, and some temperate regions of the world. The disease is caused by a parasite, Plasmodium, which belongs to a group of one-celled organisms known as protozoa. The only way to get malaria is to be bitten by a certain type of mosquito that has bitten someone who has the disease.
Anti-malarial Drugs are available only with a physician's prescription. They come in tablet, capsule, and injectable forms. Among the commonly used anti-malarial drugs are chloroquine, mefloquine, primaquine, pyrimethamine, and quinine.
Selected research
Industry Research
Drugs for Malaria Industry Research Report 2026
Market perspective
Drugs for malaria or antimalarial medications are also known as anti-malarial drugs. Anti-malarial drugs treat or Prevention malaria, a disease that occurs in tropical, subtropical, and some temperate regions of the world. The disease is caused by a parasite, Plasmodium, which belongs to a group of one-celled organisms known as protozoa. The only way to get malaria is to be bitten by a certain type of mosquito that has bitten someone who has the disease.
Anti-malarial Drugs are available only with a physician's prescription. They come in tablet, capsule, and injectable forms. Among the commonly used anti-malarial drugs are chloroquine, mefloquine, primaquine, pyrimethamine, and quinine.
In the U.S. market, the major manufacturers are Cipla, Guilin Southern Medicine, IPCA Laboratories, GlaxoSmithKline, Mylan Labs, Roche, Novartis, Sanofi Aentis and Ajanta Pharma, etc, with about 73% market shares.
Read the full market overview
Report Scope
This report quantifies the global Drugs for Malaria market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Drugs for Malaria.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Drugs for Malaria Market by Company
Cipla
Guilin Pharmaceutical
IPCA Laboratories
GlaxoSmithKline
Mylan Labs
Roche
Novartis
Sanofi Aventis
Ajanta Pharma
Drugs for Malaria Segment by Type
Aryl Aminoalcohol Compounds
Antifolate Compounds
Artemisinin Compounds
Drugs for Malaria Segment by Application
Prevention
Treatment
Others
Drugs for Malaria Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Malaria market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drugs for Malaria and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Malaria.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Drugs for Malaria companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Aryl Aminoalcohol Compounds
- Antifolate Compounds
- Artemisinin Compounds
Applications
- Prevention
- Treatment
- Others
Companies covered
- Cipla
- Guilin Pharmaceutical
- IPCA Laboratories
- GlaxoSmithKline
- Mylan Labs
- Roche
- Novartis
- Sanofi Aventis
- Ajanta Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Drugs for Malaria by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Aryl Aminoalcohol Compounds
- 2.2.3 Antifolate Compounds
- 2.2.4 Artemisinin Compounds
- 2.3 Drugs for Malaria by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Prevention
- 2.3.3 Treatment
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Drugs for Malaria Breakdown Data by Type
- 3.1 Global Drugs for Malaria Historic Market Size by Type (2021-2026)
- 3.2 Global Drugs for Malaria Forecasted Market Size by Type (2027-2032)
4 Drugs for Malaria Breakdown Data by Application
- 4.1 Global Drugs for Malaria Historic Market Size by Application (2021-2026)
- 4.2 Global Drugs for Malaria Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Drugs for Malaria Market Perspective (2021-2032)
- 5.2 Global Drugs for Malaria Growth Trends by Region
- 5.2.1 Global Drugs for Malaria Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Drugs for Malaria Historic Market Size by Region (2021-2026)
- 5.2.3 Drugs for Malaria Forecasted Market Size by Region (2027-2032)
- 5.3 Drugs for Malaria Market Dynamics
- 5.3.1 Drugs for Malaria Industry Trends
- 5.3.2 Drugs for Malaria Market Drivers
- 5.3.3 Drugs for Malaria Market Challenges
- 5.3.4 Drugs for Malaria Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Drugs for Malaria Players by Revenue
- 6.1.1 Global Top Drugs for Malaria Players by Revenue (2021-2026)
- 6.1.2 Global Drugs for Malaria Revenue Market Share by Players (2021-2026)
- 6.2 Global Drugs for Malaria Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Drugs for Malaria Head Office and Area Served
- 6.4 Global Drugs for Malaria Players, Product Type & Application
- 6.5 Global Drugs for Malaria Manufacturers Established Date
- 6.6 Global Drugs for Malaria Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Drugs for Malaria Market Size (2021-2032)
- 7.2 North America Drugs for Malaria Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Drugs for Malaria Market Size by Country (2021-2026)
- 7.4 North America Drugs for Malaria Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Drugs for Malaria Market Size (2021-2032)
- 8.2 Europe Drugs for Malaria Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Drugs for Malaria Market Size by Country (2021-2026)
- 8.4 Europe Drugs for Malaria Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Drugs for Malaria Market Size (2021-2032)
- 9.2 Asia-Pacific Drugs for Malaria Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Drugs for Malaria Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Drugs for Malaria Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Drugs for Malaria Market Size (2021-2032)
- 10.2 South America Drugs for Malaria Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Drugs for Malaria Market Size by Country (2021-2026)
- 10.4 South America Drugs for Malaria Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Drugs for Malaria Market Size (2021-2032)
- 11.2 Middle East & Africa Drugs for Malaria Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Drugs for Malaria Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Drugs for Malaria Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Cipla
- 12.1.1 Cipla Company Information
- 12.1.2 Cipla Business Overview
- 12.1.3 Cipla Revenue in Drugs for Malaria Business (2021-2026)
- 12.1.4 Cipla Drugs for Malaria Product Portfolio
- 12.1.5 Cipla Recent Developments
- 12.2 Guilin Pharmaceutical
- 12.2.1 Guilin Pharmaceutical Company Information
- 12.2.2 Guilin Pharmaceutical Business Overview
- 12.2.3 Guilin Pharmaceutical Revenue in Drugs for Malaria Business (2021-2026)
- 12.2.4 Guilin Pharmaceutical Drugs for Malaria Product Portfolio
- 12.2.5 Guilin Pharmaceutical Recent Developments
- 12.3 IPCA Laboratories
- 12.3.1 IPCA Laboratories Company Information
- 12.3.2 IPCA Laboratories Business Overview
- 12.3.3 IPCA Laboratories Revenue in Drugs for Malaria Business (2021-2026)
- 12.3.4 IPCA Laboratories Drugs for Malaria Product Portfolio
- 12.3.5 IPCA Laboratories Recent Developments
- 12.4 GlaxoSmithKline
- 12.4.1 GlaxoSmithKline Company Information
- 12.4.2 GlaxoSmithKline Business Overview
- 12.4.3 GlaxoSmithKline Revenue in Drugs for Malaria Business (2021-2026)
- 12.4.4 GlaxoSmithKline Drugs for Malaria Product Portfolio
- 12.4.5 GlaxoSmithKline Recent Developments
- 12.5 Mylan Labs
- 12.5.1 Mylan Labs Company Information
- 12.5.2 Mylan Labs Business Overview
- 12.5.3 Mylan Labs Revenue in Drugs for Malaria Business (2021-2026)
- 12.5.4 Mylan Labs Drugs for Malaria Product Portfolio
- 12.5.5 Mylan Labs Recent Developments
- 12.6 Roche
- 12.6.1 Roche Company Information
- 12.6.2 Roche Business Overview
- 12.6.3 Roche Revenue in Drugs for Malaria Business (2021-2026)
- 12.6.4 Roche Drugs for Malaria Product Portfolio
- 12.6.5 Roche Recent Developments
- 12.7 Novartis
- 12.7.1 Novartis Company Information
- 12.7.2 Novartis Business Overview
- 12.7.3 Novartis Revenue in Drugs for Malaria Business (2021-2026)
- 12.7.4 Novartis Drugs for Malaria Product Portfolio
- 12.7.5 Novartis Recent Developments
- 12.8 Sanofi Aventis
- 12.8.1 Sanofi Aventis Company Information
- 12.8.2 Sanofi Aventis Business Overview
- 12.8.3 Sanofi Aventis Revenue in Drugs for Malaria Business (2021-2026)
- 12.8.4 Sanofi Aventis Drugs for Malaria Product Portfolio
- 12.8.5 Sanofi Aventis Recent Developments
- 12.9 Ajanta Pharma
- 12.9.1 Ajanta Pharma Company Information
- 12.9.2 Ajanta Pharma Business Overview
- 12.9.3 Ajanta Pharma Revenue in Drugs for Malaria Business (2021-2026)
- 12.9.4 Ajanta Pharma Drugs for Malaria Product Portfolio
- 12.9.5 Ajanta Pharma Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst